Compare OBAI & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OBAI | LIXT |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 26.5M |
| IPO Year | N/A | N/A |
| Metric | OBAI | LIXT |
|---|---|---|
| Price | $0.53 | $4.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 30.9K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $0.64 |
| 52 Week High | $19.95 | $6.09 |
| Indicator | OBAI | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 21.65 | 69.83 |
| Support Level | $0.44 | $3.68 |
| Resistance Level | $1.66 | $4.96 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 18.73 | 96.28 |
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.